Evidence map›Paper›PMID 30622177›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2019

Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody.

Suping Zhang, Han Zhang, Emanuela M Ghia, Jiajia Huang, Liufeng Wu, Jianchao Zhang, Sharon Lam, Yang Lei, Jinsong He, Bing Cui and 8 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed
8.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 138 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Nanotheranostics: A Cutting-edge Technology for Cancer Management.Current pharmaceutical biotechnology · 2025
    Review
  17. Review
  18. Article
  19. Article
  20. Review

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 2 countries.

Suping ZhangGuangdong Key Laboratory for Genome Stability and Human Disease Prevention, Department of Pharmacology, International Cancer Center, Shenzhen University Health Science Center, 518060 Shenzhen, China.
Han ZhangMoores Cancer Center, University of California, San Diego, La Jolla, CA 92093.
Emanuela M GhiaMoores Cancer Center, University of California, San Diego, La Jolla, CA 92093.
Jiajia HuangState Key Laboratory of Oncology in South China, Department of Medical Oncology, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, 510060 Guangzhou, China.
Liufeng WuGuangdong Key Laboratory for Genome Stability and Human Disease Prevention, Department of Pharmacology, International Cancer Center, Shenzhen University Health Science Center, 518060 Shenzhen, China.
Jianchao ZhangGuangdong Key Laboratory for Genome Stability and Human Disease Prevention, Department of Pharmacology, International Cancer Center, Shenzhen University Health Science Center, 518060 Shenzhen, China.
Sharon LamMoores Cancer Center, University of California, San Diego, La Jolla, CA 92093.
Yang LeiGuangdong Key Laboratory for Genome Stability and Human Disease Prevention, Department of Pharmacology, International Cancer Center, Shenzhen University Health Science Center, 518060 Shenzhen, China.
Jinsong HeDepartment of Breast Surgery, The Peking University Shenzhen Hospital, 518036 Shenzhen, China.
Bing CuiMoores Cancer Center, University of California, San Diego, La Jolla, CA 92093.
George F WidhopfMoores Cancer Center, University of California, San Diego, La Jolla, CA 92093.
Jian YuMoores Cancer Center, University of California, San Diego, La Jolla, CA 92093.
Richard SchwabMoores Cancer Center, University of California, San Diego, La Jolla, CA 92093.
Karen MesserMoores Cancer Center, University of California, San Diego, La Jolla, CA 92093.
Wenqi JiangState Key Laboratory of Oncology in South China, Department of Medical Oncology, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, 510060 Guangzhou, China.
Barbara A ParkerMoores Cancer Center, University of California, San Diego, La Jolla, CA 92093.
Dennis A CarsonGuangdong Key Laboratory for Genome Stability and Human Disease Prevention, Department of Pharmacology, International Cancer Center, Shenzhen University Health Science Center, 518060 Shenzhen, China; dcarson@ucsd.edu tkipps@ucsd.edu.
Thomas J KippsGuangdong Key Laboratory for Genome Stability and Human Disease Prevention, Department of Pharmacology, International Cancer Center, Shenzhen University Health Science Center, 518060 Shenzhen, China; dcarson@ucsd.edu tkipps@ucsd.edu.
University of California, San Diego · USShenzhen University Health Science Center · CNSun Yat-sen University Cancer Center · CNPeking University Shenzhen Hospital · CN

Funding

Tissue CoreP01CA081534 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KIPPS, THOMAS J · 2000 to 2016
$59.5M
NCI NIH HHS P01 CA081534
6 · The paper itself

Abstract

Breast cancers enduring treatment with chemotherapy may be enriched for cancer stem cells or tumor-initiating cells, which have an enhanced capacity for self-renewal, tumor initiation, and/or metastasis. Breast cancer cells that express the type I tyrosine kinaselike orphan receptor ROR1 also may have such features. Here we find that the expression of ROR1 increased in breast cancer cells following treatment with chemotherapy, which also enhanced expression of genes induced by the activation of Rho-GTPases, Hippo-YAP/TAZ, or B lymphoma Mo-MLV insertion region 1 homolog (BMI1). Expression of ROR1 also enhanced the capacity of breast cancer cells to invade Matrigel, form spheroids, engraft in Rag2

Indexed as

Adenosine TriphosphatasesAnimalsAntibodies, MonoclonalAntineoplastic AgentsBreastBreast NeoplasmsCell Line, TumorDrug Resistance, NeoplasmFemaleGene Expression Regulation, NeoplasticHeterograftsHumansMiceNeoplastic Stem CellsNIH 3T3 CellsNuclear ProteinsAdenosine TriphosphatasesAntibodies, MonoclonalAntineoplastic AgentsNuclear ProteinsPaclitaxelPolycomb Repressive Complex 1Protein Serine-Threonine KinasesReceptor Tyrosine Kinase-like Orphan Receptorsrho-ATPaseROR1 protein, humanTranscription Factorsbreast-cancer stem cellschemotherapycirmtuzumabROR1ROR1-signaling

Identifiers

PMID30622177
PMCPMC6347692
OpenAlexW2911082000

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.